Recent progress in conventional and biologic therapy for systemic lupus erythematosus
作者： David Wofsy
DOI: 10.1136/ANNRHEUMDIS-2012-202204
关键词:
摘要: The recent approval of belimumab for the treatment systemic lupus erythematosus (SLE) ended a decade in which there was mounting optimism about prospect developing biologically based therapies SLE. During this same period, steady progress had been made understanding and applying conventional These advances use provide an important frame reference evaluating novel biologic that are expected to emerge near future.
sci-hub.se 参考文章(27)
Lena Schiffer, Jayashree Sinha, Xiaobo Wang, Weiqing Huang, Gero von Gonsdorff, Mario Schiffer, Michael P. Madaio, Anne Davidson, Short Term Administration of Costimulatory Blockade and Cyclophosphamide Induces Remission of Systemic Lupus Erythematosus Nephritis in NZB/W F1 Mice by a Mechanism Downstream of Renal Immune Complex Deposition Journal of Immunology. ,vol. 171, pp. 489- 497 ,(2003) , 10.4049/JIMMUNOL.171.1.489
, E Tsakonas, L Joseph, J M Esdaile, D Choquette, J-L Senécal, A Cividino, D Danoff, C K Osterland, C Yeadon, C D Smith, A Long-Term Study of Hydroxychloroquine Withdrawal on Exacerbations in Systemic Lupus Erythematosus: Lupus. ,vol. 7, pp. 80- 85 ,(1998) , 10.1191/096120398678919778
Andras Perl, Pathogenic mechanisms in systemic lupus erythematosus Autoimmunity. ,vol. 43, pp. 1- 6 ,(2010) , 10.3109/08916930903374741
Brad H Rovin, Richard Furie, Kevin Latinis, R John Looney, Fernando C Fervenza, Jorge Sanchez‐Guerrero, Romeo Maciuca, David Zhang, Jay P Garg, Paul Brunetta, Gerald Appel, LUNAR Investigator Group, None, Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The lupus nephritis assessment with rituximab study† Arthritis & Rheumatism. ,vol. 64, pp. 1215- 1226 ,(2012) , 10.1002/ART.34359
T Lindstein, C. June, J. Ledbetter, G Stella, C. Thompson, Regulation of lymphokine messenger RNA stability by a surface-mediated T cell activation pathway Science. ,vol. 244, pp. 339- 343 ,(1989) , 10.1126/SCIENCE.2540528
M A Khamashta, G Ruiz-Irastorza, M Ramos-Casals, P Brito-Zeron, Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review Annals of the Rheumatic Diseases. ,vol. 69, pp. 20- 28 ,(2010) , 10.1136/ARD.2008.101766
B. Finck, P. Linsley, D Wofsy, Treatment of murine lupus with CTLA4Ig Science. ,vol. 265, pp. 1225- 1227 ,(1994) , 10.1126/SCIENCE.7520604
Hyejung Jung, Raja Bobba, Jiandong Su, Zhaleh Shariati-Sarabi, Dafna D. Gladman, Murray Urowitz, Wendy Lou, Paul R. Fortin, The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus. Arthritis & Rheumatism. ,vol. 62, pp. 863- 868 ,(2010) , 10.1002/ART.27289
Joan T. Merrill, C. Michael Neuwelt, Daniel J. Wallace, Joseph C. Shanahan, Kevin M. Latinis, James C. Oates, Tammy O. Utset, Caroline Gordon, David A. Isenberg, Hsin-Ju Hsieh, David Zhang, Paul G. Brunetta, Efficacy and Safety of Rituximab in Moderately-to-Severely Active Systemic Lupus Erythematosus: The Randomized, Double-Blind, Phase II/III Systemic Lupus Erythematosus Evaluation of Rituximab Trial Arthritis & Rheumatism. ,vol. 62, pp. 222- 233 ,(2010) , 10.1002/ART.27233
Boyoun Park, Melanie M Brinkmann, Eric Spooner, Clarissa C Lee, You-Me Kim, Hidde L Ploegh, Proteolytic cleavage in an endolysosomal compartment is required for activation of Toll-like receptor 9 Nature Immunology. ,vol. 9, pp. 1407- 1414 ,(2008) , 10.1038/NI.1669